

QuickVue[®]


Results. Right. Now.



Test and Treat Today®!

- Identifies and differentiates both influenza Type A or B in positive samples, or reaches negative results in negative samples, in approx. 10 minutes or sooner, for better patient management decisions
- Most patients tested can be diagnosed and treated in just one visit
- Accurate detection with nasal/nasopharyngeal swab samples:
 81.5% PPA and 97.8% NPA for type A
 80.9% PPA and 99.1% NPA for type B
- 3 steps, 1 reagent, 90 seconds hands-on time
- Each kit contains everything needed to perform the test, including foam-tipped nasal swabs and Positive and Negative Controls
- Room temperature storage with 24-month shelf life from date of manufacture.

Nasal/Nasopharyngeal swab procedure:



QuickVue Influenza A+B Nasal/Nasopharyngeal Swab Performance versus the FDA-cleared Influenza A and B Molecular Assay (All Age Groups)

Type A

	iviolecular	
	Pos	Neg
QV Pos	190	21
QV Neg	43	924
Total	233	945

Positive Percent Agreement (PPA) 81.5% (190/233)

Negative Percent Agreement (NPA) 97.8% (924/945)

Type B

	Pos	Neg
QV Pos	89	10
QV Neg	21	1058
Total	110	1068

Molecular

Positive Percent Agreement (PPA) 80.9% (89/110)
Negative Percent Agreement (NPA) 99.1% (1058/1068)

The performance of any rapid flu test is dependent on sample collection and handling and the adherence to the Package Insert. Refer to our website at quidel.com for additional performance claims.









SL1204 | SS2018302EN00 (07/18)